Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2

Conditions

Carcinoma, Non-Small-Cell Lung 701Breast Neoplasms 630Neoplasms 584Leukemia, Myeloid, Acute 481Colorectal Neoplasms 458Multiple Myeloma 445Melanoma 426Prostatic Neoplasms 383Neoplasm Metastasis 374Pancreatic Neoplasms 364Recurrence 351Lymphoma 340Ovarian Neoplasms 325Lung Neoplasms 298Lymphoma, Non-Hodgkin 295Leukemia 287Glioblastoma 276Precursor Cell Lymphoblastic Leukemia-Lymphoma 249Stomach Neoplasms 246Leukemia, Lymphocytic, Chronic, B-Cell 235Carcinoma, Hepatocellular 232Squamous Cell Carcinoma of Head and Neck 220Lymphoma, Large B-Cell, Diffuse 217Myelodysplastic Syndromes 212Carcinoma, Renal Cell 211Lymphoma, Follicular 183Head and Neck Neoplasms 172Brain Neoplasms 169Lymphoma, Mantle-Cell 167Triple Negative Breast Neoplasms 166

Interventions

regorafenib 1Paclitaxel 1Everolimus 1Etoposide 1Cisplatin 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Unresectable Locally Advanced or Metastatic Solid Tumors × Clear all
NCT06974812 2026-01-29

IBI3014 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Innovent Biologics (Suzhou) Co. Ltd.

Phase 1/2 Recruiting
250 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

NCT06682611 2024-11-12

Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.

Shanghai Runshi Pharmaceutical Technology Co., Ltd

Phase 1/2 Not yet recruiting
380 enrolled
Other solid neoplasm

Unresectable Locally Advanced or Metastatic Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡